Tempest Therapeutics Ownership

TPST Stock  USD 6.44  0.19  3.04%   
The market capitalization of Tempest Therapeutics is $23.24 Million. About 88.14 % of Tempest Therapeutics outstanding shares are held by general public with 0.12 (%) owned by insiders and only 11.74 % by institutional holders. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tempest Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For more information on how to buy Tempest Stock please use our How to Invest in Tempest Therapeutics guide.

Tempest Stock Ownership Analysis

The book value of the company was at this time reported as 3.16. The company recorded a loss per share of 18.04. Tempest Therapeutics last dividend was issued on the 10th of December 2018. The entity had 1:13 split on the 9th of April 2025. Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc. Tempest Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people. To find out more about Tempest Therapeutics contact LLM JD at 415 798 8589 or learn more at https://www.tempesttx.com.

Tempest Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tempest Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tempest Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tempest Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Brady Stephen R over a month ago
Acquisition by Brady Stephen R of 250000 shares of Tempest Therapeutics at 4.66 subject to Rule 16b-3
 
Whiting Samuel over three months ago
Insider Trading
 
Pellizzari Christine A over three months ago
Acquisition by Pellizzari Christine A of 16000 shares of Tempest Therapeutics at 3.03 subject to Rule 16b-3
 
Whiting Samuel over six months ago
Acquisition by Whiting Samuel of 1700 shares of Tempest Therapeutics at 4.8048 subject to Rule 16b-3
 
Nicholas Maestas over six months ago
Acquisition by Nicholas Maestas of 200000 shares of Tempest Therapeutics at 0.86 subject to Rule 16b-3
 
Woiwode Thomas over six months ago
Acquisition by Woiwode Thomas of 6635 shares of Tempest Therapeutics at 11.07 subject to Rule 16b-3
 
Dubensky Thomas W. over six months ago
Acquisition by Dubensky Thomas W. of 102700 shares of Tempest Therapeutics subject to Rule 16b-3
 
Versant Venture Capital Vi, L.p. over six months ago
Disposition of 387999 shares by Versant Venture Capital Vi, L.p. of Tempest Therapeutics at 1.1005 subject to Rule 16b-3
 
Whiting Samuel over six months ago
Insider Trading
 
Justin Trojanowski over a year ago
Acquisition by Justin Trojanowski of 7500 shares of Tempest Therapeutics at 2.16 subject to Rule 16b-3
 
Raab Michael over a year ago
Acquisition by Raab Michael of 16000 shares of Tempest Therapeutics at 3.03 subject to Rule 16b-3
 
Woiwode Thomas over a year ago
Acquisition by Woiwode Thomas of 3500 shares of Tempest Therapeutics at 2.08 subject to Rule 16b-3

Tempest Therapeutics Outstanding Bonds

Tempest Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tempest Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tempest bonds can be classified according to their maturity, which is the date when Tempest Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Tempest Stock Analysis

When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.